Pramlintide as an Adjunct to Basal Insulin: Effects on Glycemic Control and Weight in Patients with Type 2 Diabetes Mellitus

[1]  J. Frias,et al.  Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. , 2007, Diabetes technology & therapeutics.

[2]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[3]  S. Doran,et al.  Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes , 2005, Diabetologia.

[4]  C. Weyer,et al.  Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. , 2005, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[5]  O G Kolterman,et al.  Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[6]  V. Fonseca.  Effect of thiazolidinediones on body weight in patients with diabetes mellitus. , 2003, The American journal of medicine.

[7]  J. Rosenstock,et al.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. , 2003, Diabetes care.

[8]  C. Weyer,et al.  Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. , 2003, Diabetes care.

[9]  C. Weyer,et al.  A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. , 2002, Diabetes care.

[10]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[11]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[12]  A. Young.  Amylinʼs physiology and its role in diabetes , 1997 .

[13]  J. Leahy.  A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes , 2007 .

[14]  C. Weyer,et al.  Weight Effect of Current and Experimental Drugs for Diabetes Mellitus , 2003, Treatments in endocrinology.

[15]  L. Want,et al.  Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. , 2002, Diabetes technology & therapeutics.